
The infusion of capital accelerates WellWith’s validation of health claims and scaling of ethical sourcing, positioning it to capture growing demand for scientifically backed natural wellness solutions in India.
The Indian wellness sector has surged in the past five years, driven by rising health consciousness and a preference for natural, plant‑based supplements. Investors are increasingly gravitating toward startups that combine traditional Ayurvedic knowledge with rigorous scientific validation, a trend exemplified by WellWith’s recent seed round. Sea‑buckthorn, a nutrient‑dense berry native to the Himalayas, has attracted attention for its antioxidant profile, making it a strategic ingredient for products targeting immunity and skin health. By securing Rs 1.25 crore, WellWith joins a wave of capital‑backed ventures aiming to professionalize the natural‑product space.
WellWith plans to allocate the new funds toward structured clinical trials, a move that could differentiate its portfolio in a crowded market where many brands rely on anecdotal claims. Simultaneously, the startup is deepening its sourcing and processing infrastructure in Ladakh, a region rich in sea‑buckthorn but challenged by logistics. Strengthening the supply chain not only ensures product consistency but also creates sustainable livelihoods for local farmers, aligning with the company’s Studentpreneur and Mompreneur initiatives. This dual focus on evidence‑based efficacy and community impact positions the brand for scalable growth.
For investors, the round signals confidence in a business model that blends ethical sourcing with data‑driven product development. As regulatory scrutiny around health supplements tightens, companies that can substantiate benefits through clinical data are likely to gain market share and command premium pricing. WellWith’s approach may also prompt larger players to adopt similar sourcing standards, potentially reshaping the competitive landscape. If the startup successfully validates its formulations and expands distribution, it could set a benchmark for Indian wellness brands seeking both profitability and social responsibility.
Gyan Vardhan · 09 Feb 2026 14:48 IST
/entrackr/media/media_files/2026/02/09/wellwith-2026-02-09-14-26-58.png)
Wellness startup WellWith has raised Rs 1.25 crore in a seed funding round led by BeyondSeed, with participation from Winner Ventures.
The fresh funds will be deployed toward advancing clinical research and strengthening supply‑chain infrastructure in Ladakh, WellWith said in a press release.
Co‑founded in 2021 by Udit Chawla, Bhupendra Pal, Arun Solanki, and Nikhil Pratap Singh, WellWith focuses on developing sea‑buckthorn–based wellness solutions informed by traditional wisdom and supported by modern scientific research. Its product portfolio addresses immunity, skin health, digestion, energy, and preventive care, with a strong emphasis on transparency, minimal processing, and ethical sourcing.
The Noida‑based startup aims to build a scalable, impact‑focused wellness business grounded in ethical sourcing, responsible growth, and long‑term value creation.
WellWith said it has demonstrated consistent revenue growth, driven by repeat purchases and strong organic demand. The company has built a pan‑India direct‑selling ecosystem focused on livelihood generation and community empowerment through initiatives such as its Studentpreneur and Mompreneur programs.
WellWith plans to invest in structured clinical studies to validate the efficacy and safety of its sea‑buckthorn–based formulations. In parallel, the company will deepen its sourcing, processing, and logistics capabilities in the Himalayan region, supporting quality, scalability, and long‑term community engagement.
Disclaimer: Bareback Media has recently raised funding from a group of investors. Some of the investors may directly or indirectly be involved in a competing business or might be associated with other companies we might write about. This shall, however, not influence our reporting or coverage in any manner whatsoever. You may find a list of our investors here.
Comments
Want to join the conversation?
Loading comments...